Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.53T +2.3%
Revenue (ttm)	1.57T +10.4%
Net Income	195.86B +691.8%
EPS	17,021.64 +691.8%
Shares Out	11.51M
PE Ratio	7.82
Forward PE	8.39
Dividend	600.00 (0.42%)
Ex-Dividend Date	Dec 29, 2025

Volume	22,638
Average Volume	30,683
Open	133,500
Previous Close	133,100
Day's Range	127,000 - 135,200
52-Week Range	128,900 - 199,400
Beta	0.07
RSI	34.83
Earnings Date	Aug 14, 2026

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2025, Daewoong Pharmaceutical's revenue was 1.57 trillion, an increase of 10.42% compared to the previous year's 1.42 trillion. Earnings were 195.86 billion, an increase of 691.83%.